Cost the focus in biosimilar debate


The cost of biosimilars for governments and patients was central to a ‘pro’ and ‘con’ debate on biosimilars at the American College of Rheumatology annual congress The highly anticipated ‘great debate’ pitted Jonathan Kay, MD, against Roy Fleischmann, MD, to attempt to sway the audience on whether it is safe, effective and cost-effective to switch patients ...


Already a member? Login to keep reading


OR
© 2017 the limbic